University of South Florida Morsani College of Medicine
Tampa, Florida, 33612, United States
NCT Number: NCT04540406
This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat early-stage suspected or confirmed symptomatic COVID-19 patients.
Looking for future studies?
Notify Me18 year–79 year
All sexes
Interventional
Phase 2
Tampa, Florida, 33612, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
a) Mild COVID-19
b) Moderate COVID-19
Exclusion criteria
Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.
Control group will also follow the same schedule except they will drink the same volume of water without NBT-NM108.
Time frame: Day 0-28
Amplicon Sequence Variants (ASVs) significantly correlated with the first principal coordinate (PC1) from the covariate-adjusted Principal Coordinates Analysis (aPCoA) were identified, each having an average relative abundance greater than 0.001%. These ASVs represent specific microbial features whose relative abundance was most strongly associated with the primary axis of variation in the microbiome data, after adjusting for covariates. It was hypothesized that PC1 might reflect the direction of microbiome changes induced by the intervention, given its association with shifts observed in participants' microbiome compositions before and after the intervention. The unit of measure used here is the relative abundance percentage of each ASV in the stool sample.
Time frame: At days 0, 14, 28, and 56
Hospitalization or death
Time frame: At days 0, 14, 28, and 56
(not specified)
Time frame: At days 0, 14, 28, and 56
Time frame: At days 28 and 56
All vitals signs are within normal range for at least 24h, including body temperature 36.4-37.5C (97.7-99.5F), pulse rate <90/min, respiratory rate 12-16/min, and oxygen saturation level at 95-100%.
Time frame: At days 28 and 56
Absence of all COVID-19-like symptoms listed by CDC (updated May 13, 2020) for at least 48h, including the presence of chills or "feeling feverish" , cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea
Time frame: At days 28 and 56
Proportion of participants who have complete resolution of subjective symptoms except fatigue and cough, i.e. absence of all COVID-19-like symptoms listed by CDC (updated May 13, 2020) for at least 48 h, including the presence of chills or "feeling feverish", cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea
Time frame: Day 0
Proportion of participants who meet each COVID-19 category in both mild, moderate, and severe categories
Time frame: At days 0, 14, 28, and 56
Time frame: At days 0, 14, 28, and 56
Time frame: At days 0, 14, 28, and 56
Time frame: At days 0, 14, 28, and 56
Time frame: At days 0 and 28
Notitia Biotechnologies Company
Industry
Modulation of Gut Microbiota With NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
Acronym: COVGUT20
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04763681
COVID-19, Coronaviridae Infections
Toronto, Ontario, Canada
View Trial DetailsNCT04747249
COVID-19, Coronaviridae Infections
Caen, France
View Trial DetailsNCT06305793
COVID-19, Chronic Disease
Durham, North Carolina, United States
View Trial DetailsNCT04794829
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial Details